India, July 12 -- Beta Drugs Ltd is a manufacturer of anti-cancer medicines having built its reputation as being one of India's top ten oncology drugmakers. Over the last two decades, the company has built a portfolio that now spans more than 50 products across tablets, capsules, oral formulations and injectables, targeting cancers of the breast, brain, bone, lung and prostate. It brought API manufacturing in-house in 2017 and extended its footprint abroad with an oncology plant in Uzbekistan the following year. More recent launches include the first Indian brands of dasatinib and sunitinib, two targeted cancer therapies. In May this year, Beta Drugs completed its most significant strategic move by acquiring a 66.1 percent stake in Nivian...